ACST Stock – (NASDAQ: ACST) is actually providing an update on the usage
As required pursuant to the policies of the TSX Venture Exchange, Acasti Pharma Inc. (“Acasti or perhaps the “Company”) ACST Stock (NASDAQ: ACST – TSX V: ACST) is providing an update on the usage of the “at the market” equity of its providing program.
As previously disclosed, Acasti entered into an amended and restated ATM sales agreement on June 29, 2020 (the “Sales Agreement”) with B. Riley FBR Inc., Oppenheimer & Co. Inc. and H.C. Wainwright & Co., LLC (collectively, the “Agents”), to carry out a “at the market” equity offering system under which Acasti may well issue and sell from time to time its everyday shares having an aggregate offering price of up to seventy five dolars million throughout the Agents (the “ATM Program”).
ACST Stock – Pursuant to the ATM Program, as necessary pursuant to the policies of the TSX Venture Exchange (“TSXV”), since the final distributions found on January twenty seven, 2021, Acasti given an aggregate of 20,159,229 typical shares (the “ATM Shares”) over the NASDAQ Stock Market for aggregate yucky proceeds to the Company of US$21.7 huge number of. The ATM Shares had been sold at prevailing market costs averaging US$1.0747 per share. No securities had been sold throughout the facilities of the TSXV or, to the knowledge of the Company, in Canada. The ATM Shares were sold pursuant to a U.S. registration statement on Form S-3 (No. 333 239538) as made effective on July 7, 2020, and the Sales Agreement. Pursuant to the Sales Agreement, a money commission of 3.0 % on the aggregate gross proceeds raised was given to the Agents in connection with their services. As a direct result of the recent ATM sales, Acasti has a total of 200,119,659 common shares issued and outstanding as of March five, 2021.
The extra capital raised has strengthened Acasti’s balance sheet and will deliver the Company with more freedom in its ongoing review process to explore as well as evaluate strategic options.
About Acasti – ACST Stock
Acasti is a biopharmaceutical innovator that has historically focused on the research, development and commercialization of prescription drugs using OM3 greasy acids delivered both as totally free fatty acids as well as bound-to-phospholipid esters, created from krill oil. OM3 fatty acids have substantial clinical proof of safety as well as efficacy in lowering triglycerides in clients with hypertriglyceridemia, or HTG. CaPre, an OM3 phospholipid therapeutic, was being formulated for clients with serious HTG.
Forward Looking Statements – ACST Stock
Statements of this press release which aren’t statements of current or historical truth constitute “forward-looking information” to the meaning of Canadian securities laws and “forward looking statements” within the meaning of U.S. federal securities laws (collectively, “forward looking statements”). Such forward looking claims include known and unknown risks, uncertainties, along with other unknown variables that might result in the actual outcomes of Acasti to be materially different from historical results and from any future results expressed or perhaps implied by such forward-looking statements. In addition to statements which explicitly describe such risks and uncertainties, people are actually urged to look at statements labeled with the terms “believes,” “belief,” “expects,” “intends,” “anticipates,” “potential,” “should,” “may,” “will,” “plans,” “continue”, “targeted” or some other similar expressions to be forward-looking and uncertain. People are actually cautioned not to place undue reliance on these forward looking statements, which speak simply as of the date of this press release. Forward-looking claims in that press release include, but are not restricted to, statements or information about Acasti’s strategy, future operations as well as its review of strategic options.
The forward-looking statements found in this specific press release are expressly qualified in the entirety of theirs by this alerting statement, the “Special Note Regarding Forward Looking Statements” section found in Acasti’s newest annual report on Form 10-K and quarterly report on Form 10-Q, which are available on EDGAR at www.sec.gov/edgar.shtml, on SEDAR at www.sedar.com and also on the investor area of Acasti’s website at www.acastipharma.com. All forward-looking claims in this press release are produced as of the day of this particular press release.
ACST Stock – Acasti does not undertake to update any such forward looking statements whether as a direct result of information which is new, future events or perhaps otherwise, except as needed by law. The forward-looking claims contained herein are also subject generally to assumptions and risks and uncertainties that are discussed from time to time in Acasti’s public securities filings with the Securities and exchange Commission and The Canadian securities commissions, like Acasti’s latest annual report on Form 10 K and quarterly report on Form 10-Q underneath the caption “Risk Factors“.
ACST Stock – (NASDAQ: ACST) is providing an update on the usage